AMINE:OXYGEN OXIDOREDUCTASE [DEAMINATING] Chemical Properties

Density 

0.319[at 20℃]

vapor pressure 

0Pa at 25℃

storage temp. 

2-8°C

form 

lyophilized powder

color 

White to off-white

biological source

human

Water Solubility 

102g/L at 30℃

InChI

InChI=1/C7H15N2O6P/c8-5(7(11)12)2-1-3-9-6(10)4-16(13,14)15/h5H,1-4,8H2,(H,9,10)(H,11,12)(H2,13,14,15)/t5-/s3

InChIKey

FCIHAQFHXJOLIF-GQMHJJTINA-N

SMILES

C(O)(=O)[C@@H](N)CCCNC(CP(O)(O)=O)=O |&1:3,r|

LogP

-3 at 23℃

CAS DataBase Reference

9001-66-5

Safety Information

Safety Statements 

23-24/25

WGK Germany 

3

MSDS

• Language:English Provider:SigmaAldrich

AMINE:OXYGEN OXIDOREDUCTASE [DEAMINATING] Usage And Synthesis

Uses

Monoamine oxidase (EC 1.4.3.4) is an enzyme composed of different polypeptides. Monoamine oxidation catalyzes the oxidative deamination of various biological amines in brain and peripheral tissues by producing hydrogen peroxide. Monoamine oxidase plays an important role in maintaining the regulation of synaptic transmission, emotional behavior and other brain functions[1][2].

Definition

An enzyme that is distributedwidely among animals. It inactivates a number ofbiogenic amines by catalyzing the oxidative deam-ination of these compounds.

Flammability and Explosibility

Not classified

Biological Activity

The protein VAP-1 (vascular adhesion protein-1) belongs to the group of semicarbazide sensitive amine oxidases (SSAO) th at catalyze the formation of reactive oxygen species. It is a unique adhesion molecule th at participates in inflammatory leukocyte recruitment in blood vessels. It functions in leukocyte extravasation to inflamed tissues. In the human eye, it has been associated with ocular inflammatory diseases, such as uveitis, age-related macular degeneration, and diabetic retinopathy. Its expression has been observed to be altered in several diseases, such as rheumatoid arthritis, diabetes, and atherosclerosis.

References

[1] Shih JC, et al. Monoamine oxidase: from genes to behavior. Annu Rev Neurosci. 1999;22:197-217. DOI:10.1146/annurev.neuro.22.1.197
[2] Bortolato M, et al. Monoamine oxidase inactivation: from pathophysiology to therapeutics. Adv Drug Deliv Rev. 2008 Oct-Nov;60(13-14):1527-33. DOI:10.1016/j.addr.2008.06.002
[3] Youdim MB, et al. The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci. 2006 Apr;7(4):295-309. DOI:10.1038/nrn1883

AMINE:OXYGEN OXIDOREDUCTASE [DEAMINATING](9001-66-5)Related Product Information

• Tris(2,4-pentanedionato)chroMiuM(III)
• TRIS(2,2,6,6-TETRAMETHYL-3,5-HEPTANEDIONATO)EUROPIUM(III)
• TRIS(2,2,6,6-TETRAMETHYL-3,5-HEPTANEDIONATO)DYSPROSIUM(III)
• METHYL ISOCYANOACETATE
• Tosylmethyl isocyanide
• 2,4-PENTANEDIONE, SILVER DERIVATIVE
• PHENYLSELENOL
• 1,1,3,3-TETRAMETHYLBUTYL ISOCYANIDE
• TERT-BUTYL ISOCYANIDE
• N-BUTYLISOCYANIDE
• DICHLORO(ETHYLENEDIAMINE)PLATINUM(II)
• Ferric acetylacetonate
• Cupric acetylacetonate
• COBALT(II) ACETYLACETONATE
• SALCOMINE
• Aluminum acetylacetonate
• Ethyl isocyanoacetate
• Benzyl isocyanide